Telehealth monitoring for patients with inflammatory bowel disease
The Effect of Telehealth Monitoring on Medication Compliance, Self-Efficacy and Quality of Life in Patients With İnflammatory Bowel Disease
This study tests if a nurse-led telehealth program can help people with inflammatory bowel disease stick to their medications and improve their quality of life compared to regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Istanbul University - Cerrahpasa Academic / other |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT06971627 on ClinicalTrials.gov |
What this trial studies
This randomized controlled trial evaluates the impact of a nurse-led telehealth monitoring program on medication adherence, self-efficacy, and quality of life in individuals with inflammatory bowel disease (IBD). Participants will be randomly assigned to either an intervention group receiving a structured telehealth program or a control group receiving standard care. The intervention includes educational materials, video content, group sessions, and regular phone calls over a 12-week period. Outcomes will be assessed using validated tools at baseline and after the intervention to determine effectiveness.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with inflammatory bowel disease who are in clinical remission and can engage with telehealth technology.
Not a fit: Patients with psychiatric or cognitive disorders, advanced chronic diseases, or those receiving infusion-based treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve medication adherence and quality of life for patients with inflammatory bowel disease.
How similar studies have performed: Previous studies have shown promising results with telehealth interventions in chronic disease management, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals aged 18 years or older * Individuals aged 18 years or older * Able to read and write in Turkish * Diagnosed with inflammatory bowel disease (IBD) for at least 6 months * In clinical remission (Harvey-Bradshaw Index score \< 5 or Simple Clinical Colitis Activity Index score \< 3) * Able to use a smartphone * Have access to an online messaging application (e.g., WhatsApp) and a valid e-mail address * Capable of downloading and using a mobile or computer-based video conferencing application (e.g., Zoom) * Willing to participate in the study voluntarily Exclusion Criteria: * Diagnosed with any psychiatric or cognitive disorder * Having any condition that impairs communication * Pregnant women * Patients receiving infusion-based treatment * Having an advanced chronic disease
Where this trial is running
Istanbul
- Istanbul University - Cerrahpasa Cerrahpaşa Faculty of Medicine Department of Gastroenterology — Istanbul, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: Kimya Kılıçaslan, PhD Candidate — Istanbul University - Cerrahpasa Institute of Graudate Studies
- Study coordinator: Kimya Kılıçaslan, PhD Candidate
- Email: kimya.kilicaslan@iuc.edu.tr
- Phone: +90 535 083 45 53
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.